Tags Posts tagged with "cbd"


0 1326

PotNetwork Holding, Inc. (POTN) Restocks Popular CBD Chill Gummies Inventory


PotNetwork Holding, Inc. (OTC Pink: POTN) is pleased to announce that Diamond CBD’s Chill Gummy line has been restocked and is once again available for sale. “We are happy to announce that our popular Gummy Bears and other gummy edibles once again grace our shelves. As a result of an overwhelming influx of inquiries, we have opted to publicly announce that our gummies are stocked, available and ready to be shipped,” stated Maria Gomez, Regional Vice President of Sales, Diamond CBD.



Click Here Now To Read (POTN) Release

Why Should You Invest in Marijuana Stocks ?

When it comes to investing in marijuana (specifically medical marijuana) there are many reasons why it’s a smart move. Because of the new nature of the market, the potential for gain remains incredibly high as predictions for future charts project upwards of $5 billion in growth in the next decade. The time to get in is now.

Click Here Now To Read Full Article



One CBD Company That Could Be Outpacing Industry Leaders

Among the many segments of the marijuana industry that marijuana stock traders pay attention to, CBD or cannabidiol has taken on a major role. This is not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market is projected t to see, CBD companies are in the spotlight

Click Here Now To Read Full Article


0 1351

PotNetwork Holding, Inc. (POTN) With over $2.1 Million in Total Revenues

PotNetwork Holding, Inc. (OTC Pink: POTN) is pleased to announce today that its wholly owned subsidiary, Diamond CBD, Inc., after a strong record breaking first quarter, continues building momentum into the summer with heightened expectation for Diamond CBD’s highly sought after consumable product line. After the past two months of this quarter, revenue totals have reached $2,106,245.87, considerably exceeding the Company’s first quarter results.

Click Here Now To Read (POTN) Release

InCaseYouMissedIt: Your Marijuana Stocks Portfolio Could Benefit from CBD Companies

A great deal of progress is being made on learning how marijuana’s chemical cannabinoids can be used as medicine, and among the most interesting of these marijuana compounds is cannabidiol their wise known as CBD. It’s one of at least 113 active cannabinoids found in marijuana, it’s not responsible for marijuana’s psychoactive effect, and it accounts for about 40% of the marijuana plant’s extract.

Click Here Now To Read Full Article



Marijuana Supply In Nevada: A State Of Emergency?

Nevada’s governor has authorized a state of emergency declared for recreational marijuana regulations, after the state’s tax authority reported that many stores are running out of marijuana.

Click Here Now To Read Full Article

0 2367

A great deal of progress is being made on learning how marijuana’s chemical cannabinoids can be used as medicine, and among the most interesting of these marijuana compounds is cannabidiol their wise known as CBD. It’s one of at least 113 active cannabinoids found in marijuana, it’s not responsible for marijuana’s psychoactive effect, and it accounts for about 40% of the marijuana plant’s extract.

At the forefront of research into CBD’s use as a medicine is GW Pharmaceuticals (NASDAQ: GWPH), a U.K. drug developer that currently markets a tetrahydrocannabinol (THC)-derived drug in Europe for the treatment of muscle spasms in multiple sclerosis patients.

Is CBD The True Medical Catalyst Of Marijuana?

GW Pharmaceuticals recorded data from three separate scientifically controlled tests this past year identifying that its purified CBD, Epidiolex, reduces seizures by about 40% in patients with rare forms of childhood-onset epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.

GW Pharmaceuticals’ findings back up anecdotal evidence that CBD heavy marijuana strains and oils provide relief to epilepsy patients. Perhaps the most well known of these high CBD strains is Charlotte’s Web, which has extremely low THC content (0.3%), and was named after the childhood epilepsy patient it was created to help.

In states that have passed medical marijuana legislation, growing evidence of cannabidiol’s efficacy in epilepsy patients is leading to greater availability at marijuana dispensaries. At last count, 28 states have passed medical marijuana laws, and 16 states have passed laws allowing the prescription of CBD oil.

Epidiolex isn’t commercially available yet, but it could be within a year. GW Pharmaceuticals hopes to file for Food and Drug Administration approval of Epidiolex soon, and an official decision would come within 10 months of that filing.

If Epidiolex becomes victorious in getting a regulatory green light, it will provide advantages to doctors and patients over CBD heavy marijuana strains and oils. While Epidiolex has been scientifically proven to work, the same rigorous proof isn’t available for CBD products like Charlotte’s Web that are sold at dispensaries. If Epidiolex is approved, it will be available nationally, regardless of each state’s laws, and that means it skirts risks associated with a federal crackdown on marijuana dispensaries by Washington. Furthermore, an FDA blessing would likely convince doctors who are otherwise hesitant to recommend medical marijuana to prescribe it.

0 3952
marijuana stock

Among the many segments of the marijuana industry that marijuana stock traders pay attention to, CBD or cannabidiol has taken on a major role. This is not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market is projected t to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that has been attracting the attention of marijuana investors has been Potnetwork Holdings, Inc. (POTN).  Now don’t let the name fool you, this company, through its subsidiary First Capital Venture Co., owns Diamond CBD Inc.;

Over the last few months, POTN has been breaking barriers with its CBD brand while also hitting major milestones for the better part of the first half of the year.  What could be best of all is that 2017 may already have the stage set for a record setting period in POTN’s company history.

Big Growth Already In Play?

In May of this year (2017) the company announced that it had realized first quarter figures that exceeded expectation by over $100,000, for a total of $1,858,347.48. They also established a merchandising pipeline of 7,000 authorized retail vendors through its distribution channels, which puts Diamond CBD at approximately 10,000 stores in the United States.

If this wasn’t enough, POTN further catapulted off of this first quarter momentum by recognizing over $2million from April to mid-May with a pace set to outshine the first quarter figure by a relatively large margin. Even assuming this rate of revenue generation and accounting for zero growth or contraction in revenues, POTN could be an $11million company by year’s end. Again this is assuming the company holds this course and does about $1million in revenue per month.

Let’s compare just by Revenue Figures Alone From Most Recent Annual Filings:

√ Medical Marijuana, Inc. 

$8.00m (Annual, 2016) Market Cap: $264.7M

√ Rocky Mountain High Brands, Inc.

$1.08m (Annual, 2016)   Market Cap: $ 53.4M

√ mCig, Inc.  

$4.5m (Annual, 2017)  Market Cap: $ 70.0M

√ Axim Biotechnologies, Inc.

$0.047m (Annual, 2016) Market Cap: $551.4M

Now look at these figures, the multiples are astronomical compared to their market caps:

  • mCig trades at roughly 15.5 times revenue
  • Medical Marijuana Inc. trades at nearly 33 times revenue
  • Rocky Mountain trades over 49.4 times revenue
  • Axim is trading at an astronomical 11,732 times revenue!

Now look at the same situation for Potnetwork. We can look at the 2016 annual for apples to apples comparison but the real story comes when you consider that Diamond CBD is now its subsidiary (which we’ll get into in a moment).

√ Potnetwork Holding, Inc.     

$1.03m    (Annual, 2016)   Market Cap: $38.2M

Even with last year being a slower year for the company, which could be attributed to the company’s future outlook and its uncertainty, Potnetwork had only traded at roughly 4 times revenue.

Now, let’s take into account the company’s last few months of announcements. By the figures given, it’s assumed that as of the end of May, Potnetwork revenue was in the ballpark of roughly $3.86m on a conservative estimate based on Q1 revenue and May revenues of over $1million: first quarter 2017 revenue of $1,858,347.48, “over $1 Million in April,” and “over $1Million for May.”

Price Target Given: $0.25

Being that this will be the first time that Diamond’s operations will be under the POTN flag, we can look at a brief snapshot of the company, at least from a first half standpoint of this year.

Even by just assuming that this company sees zero growth ahead and an outstanding share count of even 600m, at current prices of roughly $0.08, POTN would be a $48m market cap company with revenues of roughly $3.86m; only 12 times revenue.

But so far this year, a “zero growth” scenario has not been the case at all. In fact, based on recent announcements, growth for the company has been very pronounced so far. This is most likely a big reason why analysts are finding that the valuation for POTN is low right now. SeeThru Equity initiated coverage on Potnnetwork Holdings and recently gave a price target of $0.25. Meanwhile, the company continues to hit the convention circuit to build attention around the investment side of Potnetwork & Diamond CBD’s company as well as the actual product side of the business through countless tradeshow appearances.

And just recently the company announced that it has sold 80,000 Chill gummies since taking to the roadshow circuit. And currently POTN is “re stocking” over a two-week period to re-up its inventory of this brand.

The takeaway? In our opinion, compared to other presumed “industry leaders,” POTN is still trading at a fraction of the revenue multiple that these other companies are. Additionally, based on announcements, it doesn’t appear that the company, with Diamond CBD, is closing the doors and stopping its revenue growth anytime soon. This could be one of the more, if not the most undervalued CBD stocks in the market right now and the fundamentals show rapid growth projected along the way.

 “We are ecstatic with our results. We have learned to set our expectations high. As a result of the timing of CBD’s growing popularity and the quality of our products, our products are consistently met with reseller and consumer enthusiasm resulting in continuous escalating sales.”

-Maria Gomez, Regional Vice President of Sales for Diamond CBD, Inc.

The opportunity for taking advantage of the growth that CBD is beginning to see could be important to take into consideration.  Figures estimate that the CBD market will grow to a $2.1 billion market in sales by 2020. That’s a 700% increase from 2016.

Think about this for a moment: POTN is already growing and is expecting to continue this growth for the year, according to several announcements already made during the last few months…this is all going to happen during a time where the CBD industry as a whole is also anticipating significant growth.

Having already come off of a banner quarter, we think that preliminary guidance from the company would suggest that this is something to be paying close attention to during the second half of 2017.


Pursuant to an agreement between MAPH and Potnetwork Holdings, Inc., we were hired for a period of 1 month from 6/1/2017 – 7/1/2017 to publicly disseminate information about (POTN) including on the Website and other media including Facebook and Twitter. We are being paid $21,000 (CASH) by Potnetwork Holdings, Inc. via First Capital Ventures, Inc. an affiliate company for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (POTN) which we purchased in the open market.We may buy or sell additional shares of (POTN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 3007

The emergence of the legal cannabis industry has created an unprecedented opportunity for investors. Although this burgeoning industry is already a multi-billion-dollar business, it is not even in the first inning of what will be multi-decade growth super cycle.

The biotech industry will be one of the greatest beneficiaries of the legal cannabis industry. From Israel to the United States, the number of studies on the medical benefits of cannabis continues to increase and to provide exciting results.

The cannabis plant has over 100 known chemical compounds but the two best known are cannabidiol (CBD) and tetrahydrocannabinol (THC). Although CBD has a much shorter history than THC, recent research studies have significantly increased our understanding of its medical benefits and its popularity continues to grow.

CBD is an appealing option for patients who are looking to treat ailments such as pain, anxiety, psychosis, seizures, spasms, to just name a few. It also does not have the primary psychoactive ingredient found in THC, which gets the user high.

A Miracle Plant with Endless Benefits

Cannabis has the potential to treat countless debilitating conditions. From epilepsy to multiple sclerosis, cannabis can improve daily life for millions of people across the globe and we need to recognize it for what it is, a medicine. Unlike other pharmaceutical drugs such as opiates or benzodiazepines, cannabis does not require you to take another type of drug to combat its side effects.

Although medical cannabis still has a way to go before it will be accepted as a medical treatment, there have been several developments with regard to its medical benefits and we want to highlight five of the known benefits of CBD.


Over the last two years, we have heard some incredible stories from the parents of children who were having more than 300 seizures a day. These children were being prescribed large doses of prescription drugs such as benzodiazepine, which did not solve the problem and had a negative impact on the child’s demeanor.

The growing number of research studies and stories from the parents of children who have benefited from CBD have led to an influx in the number of parents using CBD as a treatment. Many parents have said that CBD is an effective treatment that has reduced the frquency of daily seizures by more than 95%.

The benefits that CBD has had for patients with epilepsy has been a catalyst for the legal cannabis movement as we have seen a significant increase in the number of states with a limited medical cannabis market, which allow only strains with very low THC and high CBD.

Crohn’s Disease

Researchers and scientists have said CBD could be an effective treatment for Crohn’s Disease. In 2015, researchers in Israel conducted a study which reported significantly lower symptoms in 10 out of 11 patients with Crohn’s disease. The study said five of those patients saw a complete remission from the treatment.

Many researchers talk about the entourage effect and how cannabis works best as a medical treatment when all molecules in cannabis are present, even in a very minor capacity (less than 0.1%). When it comes to Crohn’s, it has been found that the interaction of THC and CBD helps control stomach functions, a major benefit for Crohn’s patients. Cannabis has an anti-inflammatory component providing relief to those suffering from Crohn’s.

Post-Traumatic-Stress-Disorder (PTSD)

One of the major benefits of CBD is its ability to produce anti-anxiety and anti-inflammatory effects when ingested. This is very helpful for patients who suffer from PTSD since it slows everything down (including the mind) and calms the user.

People suffering from PTSD can become overcome with anxiety and stress and anecdotal evidence shows that CBD can help treat these symptoms. The antipsychotic benefits of CBD provide relief to patients in need of a more stable emotional environment.


One of the most well-known and well-documented medical benefits associated with cannabis is its ability to treat pain. In 2011, researchers said that cannabis may help relieve pain for people suffering from rheumatoid arthritis.

CBD can help reduce pain associated with a wide variety of illnesses and debilitating diseases. From cancer to fibromyalgia, from irritable bowel syndrome to neuropathic pain, CBD can help throughout the treatment and the recovery process.

Multiple Sclerosis

Nasdaq-traded GW Pharmaceuticals’ (GWPH) developed and commercialized Sativex, the world’s first cannabis-derived product for the treatment of spasticity due to multiple sclerosis. Sativex is sold in 29 countries and is also being developed as a treatment for neuropathic pain (in Phase 2 Clinical trials).

0 910

Cannabidiol otherwise known as CBD is a compound found in marijuana. Though there are dozens of cannabinoids, which are the chemical properties found in marijuana products that create the effects linked with cannabis consumption, CBD is one of the most plentiful. It’s second only to THC.

On December 15 the DEA concluded their decision to add CBD oil to the Schedule 1 drug list, which means it must meet certain standards.

The federal government named marijuana a Schedule I drug in 1970 primarily for the psychoactive effects of THC. Prior to December, CBD remained in a regulatory gray area.

A Schedule I drug must meet three criteria to be included on the list:

1.The drug or substance has a high potential for abuse.
2.The drug or substance has no currently accepted medical use in the United States.
3.There is a lack of accepted safety standards for use of the drug or other substance under medical supervision.

The CBD classification was made despite recent investigative studies that has preliminarily shown CBD to have anti-inflammatory, analgesic as well as anti-anxiety properties without the psychoactive effects of THC.

Most of the investigative research is still in its beginning stages and opponents of the reclassification complain that CBD fails to meet the Schedule I criteria based on the initial discoveries.

Although CBD is a cannabis component, the CBD-specific industry is a little different from the larger cannabis industry.

“We do have THC-CBD products, but in the recreational industry we are not allowed to sell anything that doesn’t also have THC in it,” said Amanda Woods, Compliance Officer and Marketing Manager for Choice Organics. “So, a lot of the CBD products free-floating throughout the market were derived from hemp, which does not have the same regulations that cannabis does.”

Hemp is most commonly defined as a legal cannabis product derived from the plant’s stem. Hemp has been used for many different purposes from rope to textile fibers to nutritional supplements to medicinal oils. To be defined as hemp, the product must contain very little THC — less than one percent. For comparison, THC levels in medical cannabis are anywhere between five and 20 percent.

Hemp that contains minimal THC can still contain high amounts of other cannabinoids, like CBD. In Colorado and nationwide, you can walk into a gas station—not even a licensed dispensary— and find CBD products made from hemp. However, these products come from unregulated sources and may pose a public safety hazard.

“[Before December], CBD-only products derived from hemp could be distributed nationwide. You could send CBD in the mail and you could order it on Amazon,” Woods said.

Without the THC, hemp products avoided the strict regulations legal cannabis advocates have fought for.

“On one hand, the [rescheduling] is a step in the right direction in that it forces regulation of this gray market. Like cannabis, it will be up to the State to decide to regulate hemp like cannabis if there is to be an intra-state market. Regulation is good for everyone,” Woods said. “But it is also unfortunate because it was made into a Schedule I drug which only reinforces the federal prohibition on cannabis products… So, there was no real change for the cannabis industry in Colorado, but it has a major impact on the hemp industry.”

0 2352

From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), government agencies continue to change its stance pertaining to medical cannabis.

Last year, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells. The NIDA revised their April 2015 publication to say that marijuana can kill certain cancer cells and reduce the size of others.

Cannabis Biotech Industry Offers Incredible Potential

The biotech sector will be one of the greatest beneficiaries of the legal cannabis movement and we are favorable on the some of the opportunities within it. Cannabis biotech bellwether GW Pharmaceuticals (GWPH: Nasdaq) has fallen more than 10% from its March highs and we think investors should be keeping a close eye on the shares during this time.

Last week, the American Academy of Neurology (AAN) issued a press release highlighting the positive results from GW’s second Phase 3 study of Epidiolex in children and adults with Lennox-Gastaut syndrome (LGS). The data will be presented after the market closes on Tuesday at the AAN’s Annual Meeting in Boston.

Deep Pipeline of Products to Create Catalysts for Years to Come

We continue to view GW as one of the best cannabis investment opportunities and believe the recent pullback has created a great opportunity for new investors. The company has a 20+ year operating history, a deep pipeline of products in advanced stages of FDA testing, and a balance sheet that is strong enough to support the cost of clinical trials.

2016 was a banner year for GW as the company advanced several clinical programs in its pipeline of cannabinoid product candidates. Earlier this year, GW provided an update on its product portfolio. Highlights include:

• CBDV Phase 2 partial-onset epilepsy study in adults is ongoing as Part A is complete and Part B is underway with data expected mid-2017
• CBDV pre-clinical research is ongoing within the field of autism spectrum disorders. Phase 2 trials expected to commence in the third quarter of 2017.
• The company received the Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome
• In December, GW commenced Phase 1 trials for its Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
• The company received the Orphan Drug Designation from the FDA and EMA
• THC:CBD for the treatment of Recurrent Glioblastoma Multiforme (GBM). Phase 1b/2a study has been completed and data is in the first quarter of 2017. The company received the Orphan Drug Designation from FDA
• Sativex Phase 2 study in children with spasticity due to cerebral palsy has been completed and data is in

The Value is in the Plant

We continue to view GW Pharmaceuticals as one of the top investment opportunities within the cannabis sector as it is the only Nasdaq traded company focused on developing treatments from the actual cannabis plant.

Unlike Zynerba Pharmaceuticals (ZYNE) which develop its treatments from synthetic cannabis, GW uses the actual cannabis plant and the benefits of this are reflected in its continued success in FDA trials.

GW’s most significant product in its pipeline is Epidiolex and the company has an orphan epilepsy program in Dravet syndrome, LGS, Tuberous Sclerosis Complex (TSC) and infantile spasms (IS). Since March 2016, the company has:
• Reported positive results in a pivotal Phase 3 Dravet syndrome trial
• Reported positive results in two pivotal Phase 3 LGS trials
• Phase 3 trial in TSC ongoing
• Two-part Phase 3 trial in IS commenced in December 2016

GW has a lot of long-term potential and the company is the clear leader in the cannabis biotech industry. Investors should put GWPH on their radar and watch how the company’s research and clinical trial results not only benefit its shareholders, but the entire cannabis industry.


Authored by: Michael Berger

0 1643

Wisconsin’s legislators recently voted on a proposal that would allow patients with specific conditions to possess and use CBD oil with a physician’s recommendation. At the time there was only one vote against it out of both chambers, which was a big deal after prior legislation a couple years back had been significantly voted against. The proposal was then sent over to Governor Scott Walker, who has just finally signed the bill into law this week, making it official that CBD oil is legal for patients to use in Wisconsin. Walker stated, “Today, we’re making it easier for people in our state to obtain CBD oil without a psychoactive effect to treat a medical condition as advised by their doctor.”

Unfortunately, there are a few downsides to this particular law; the biggest one being a lack of in-state production and dispensing of the oil. The bill did not create any means for licensing cultivation facilities, processing companies or dispensaries; meaning it creates no legal access to the medicine patients so desperately need. It also doesn’t specify where patients are expected to obtain the oil, whereas some states with similar legislation in place have at least made a suggestion, even when that suggestion is to break federal law and cross state lines with the cannabis oil.

Parents with children suffering from seizure conditions may be able to rest easy about what would happen if they were discovered to have CBD oil. However, this bill really doesn’t make as much of a difference as legislators would like to think. Until there is a safe and legal way for patients to access the cannabis oil there will still be the question of how they are supposed to get the medicine once a physician finally gives them the go-ahead for treatment.

In states with CBD laws like this the only option is to get it illegally, either from someone in state on the illegal market or from a state that will accept out of state medical marijuana registration cards. This doesn’t save parents from having to be criminals just to medicate their children. It only provides protection once they are already in possession of the medicine and that’s just not enough. While it is a great thing to see legislators nearly unanimously make the decision to go against allow patients suffering from seizure conditions to use CBD oil, it is honestly not doing enough to really help these patients.

0 1721

$VPRB Brands HONEYSTICK and Gold Nugget Extracts Will Be Teaming Up

VPR Brands, LP ( OTC PINK : VPRB ) and Gold Nugget extracts will be teaming up for the High Times Cannabis Cup So-Cal April 21-23. Gold Nugget Extracts will officially be powered by our flagship vaporizer the HONEYSTICK. Our Vaporizers will be paired with Gold Nugget top shelf extracts in various categories under jointly branded units. The VPR Brands HONEYSTICK team will also be sharing sales and marketing booth with Gold Nugget Extracts at the event targeting both vendors & retail consumers.

Click Here Now To Read Full PR

$MCIG Grow Contractors Launches Greenhouse Website Portal

Grow Contractors, Inc., (GC) a wholly owned subsidiary of mCig, Inc. ( OTCQB : MCIG ), a diversified company servicing the legal Cannabis, Hemp, and CBD markets, launched its new greenhouse website at www.growcontractors.org/greenhouses/

Rob Kressa, GC’s CEO, stated, “The new open disclosure standard for the greenhouse selling portal is just the first step in our progression to becoming the nation’s largest greenhouse supplier in the cannabis grow and herbal farming markets. Since we announced our exclusive agreement with Sangreen for distribution of greenhouses at half the cost of the current market price, we have spent the past few months perfecting the design and supply lines.”

Click Here Now To Read Full PR

$ADVT Gets Largest Order to Date from SpeedWeed

ADVANTIS CORPORATION ( OTC PINK : ADVT ) announced today that SpeedWeed, California’s largest Collective, placed what has become for Advantis, their largest order to date. Advantis further announced, among other positive news, that their 1st quarter revenues are up 300% from the previous quarter. Advantis also announced that they received their first order from Arsenal, a large collective in San Diego. According to Advantis CEO Christopher Swartz, “This new technically-driven collective has placed its initial order and will begin carrying our entire product line next week.”

Click Here Now To Read Full PR

Virginia Moves Forward In Marijuana Reform, Decriminalizing CBD

Two marijuana reform bills were recently signed by Virginia Governor Terry McAuliffe (D), ending the state’s automatic six-month driver’s license suspension for first time possession offenders and allowing the production of CBD oil. This may look like a couple drops in a raging storm of national decriminalization, but NORML Executive Director, Erik Altieri, said it’s a huge accomplishment.

Click Here Now To Read Full Article

Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. We may buy or sell additional shares of (VPRB) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Unsubscribe | To contact us please reply to this email | PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1446
cbd stocks

Two marijuana reform bills were recently signed by Virginia Governor Terry McAuliffe (D), ending the state’s automatic six-month driver’s license suspension for first time possession offenders and allowing the production of CBD oil. This may look like a couple drops in a raging storm of national decriminalization, but NORML Executive Director, Erik Altieri, said it’s a huge accomplishment.

Altieri stated, “The two measures signed into law in Virginia this week may seem like baby steps, but they are the culmination of years of dedicated advocacy and legislative outreach. While neither of these bills will end the arrest of around 18,000 Virginians a year for marijuana possession or create an ideal, accessible medical marijuana program, they represent important progress in terms of growing legislative support for marijuana law reforms.”

When Senate Bill 1091 (which ends Virginia’s automatic ID suspension penalty) goes into effect at the beginning of July, it will be left at the court’s discretion whether or not to impose this condition as a term of probation, and convicts will still be subject to other conditions under Virginia law, including substance abuse screening, drug testing and community service. Minors are still subject to automatic license suspension under the new law.

For many years Virginia has all but topped the list of places you didn’t want to be caught with marijuana. In recent years Virginia has seen quite the increase in enforcement. According to data collected by the Drug Policy Alliance, marijuana possession arrests increased from approximately 13,000 in 2003 to almost 23,000 in 2014, an increase that was especially pronounced in majority Black neighborhoods.

Now that McAuliffe’s put pen to paper, the state should begin to see continued progress in this area, which has already seen some improvement since 2014. This past December, Newport News reported that the number of people arrested or charged with marijuana offenses had fallen by 14% statewide over a two-year stretch. This is step in the right direction, but putting real decriminalization laws on the books is the real answer to ending the waste and social destruction of cannabis prohibition. Keeping strict laws on the books but applying lenient, quasi-enforcement standards creates the potential for serious trouble.

Under “selective enforcement,” those who are most affected and targeted by law enforcement now; communities of colors would continue to carry that burden. In the three years from 2011 to 2013, marijuana possession arrests increased by 1,987 in Virginia; black people accounted for 82% of that increase. The Marijuana Policy Project referred to SB 1027 as an “extremely narrow law.” It will allow those suffering from intractable epilepsy to access CBD oils produced in state by Department of Health-approved pharmaceutical companies.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements